ClinicalTrials.gg
Not yet recruitingNCT06807827COGNIPHARM-IIUpdated Feb 4, 2025

Pharmacist-Led Cognitive Behavioral Intervention for Diabetic Patients: a Randomized Interventional Trial to Evaluate the Impact on Medication Adherence and Quality of Life

An interventional study of Pharmacist-led Cognitive Behavioral therapy and Basic Education in Diabete Mellitus, sponsored by Hamdard University. Not yet recruiting at 1 site in Pakistan. Open to participants aged 25 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-02-04.

Sponsored by Hamdard University · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2025, 1 year 3 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
385
Allocation
Randomized
Ages
25 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 77 studies in Diabetes Mellitus with a site in Pakistan — 23 open to participants now, 28 under way, 2 of them phase 3. Diabetes Mellitus · Pakistan.

Planned enrollment
5th of 63
385 · median 100
Started
2025
with 11 others
No phase
52 of 77
16 open now
Primary completion
2025-07
later than 11 of 27 live
Registered
50th of 77
by date
Lead sponsor
2 of 77
Hamdard University

Among the 77 studies in Diabetes Mellitus with a site in Pakistan, this one is the 5th largest by planned enrollment of the 63 interventional ones that give a count, is one of 12 that started in 2025, is one of 52 with no phase, reaches primary completion later than 11 of the 27 other live ones, and was the 50th registered.

Diabetes Mellitus

8,295 studies on the registry are indexed under Diabetes Mellitus; 1,071 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

23 of the 77 studies in Diabetes Mellitus with a site in Pakistan are open now. Recruiting first, the newest first:

18 more — sign in →

All 23 open studies →

A study can be open while its sites in Pakistan have not opened yet or have stopped. Only those recruiting at a site in Pakistan →

Who these studies take

Of the 649 Diabetes Mellitus studies recruiting now, 358 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.

This study: 25 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 77 studies in Diabetes Mellitus with a site in Pakistan, or all of them as a file.
02

Study summary

This interventional study will to assess the impact of pharmacist-led educational intervention along with cognitive behavioral intervention in diabetic patients. Participants of this study will be provided regular counselling or cognitive behavioral intervention and educational material as part of their routine pharmacy visit. Researchers will compare the two groups to see which of the two groups improve in term of medication adherence and quality of life.

Read the detailed description

The purpose of the study is to investigate whether incorporating pharmacist-led educational interventions along with Cognitive Behavioral Therapy (CBT) can result in better outcomes for diabetic patients. Effective diabetes management requires proper education and adherence to medication. Missed doses or irregular medication use can lead to poor glycemic control and increased complications. The study will examine if educational interventions along with Cognitive Behavioral Therapy (CBT) can have a favorable effect on various aspects of diabetes management coping techniques, Medication beliefs, reduction in hypo and hyperglycemic frequency, HbA1c and medication related problems (MRPs) medication adherence and overall quality of life of diabetic patients.

03

Conditions studied

  • Diabete Mellitus

Keywords

  • Educational Intervention
  • Cognitive behavioral therapy
  • Pharmacist
  • Medication Adherence
  • Quality of life
04

Who can participate

Ages eligible
25 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All confirmed Type II diabetic patients who visit endocrinology OPD Clinic during study duration.

Patients having >8%. Follow up as well as new patients were included subjects willing to participate in the study with or without other severe co-morbidities were included in the study.

Exclusion criteria

Exclusion Criteria:

GDM diabetic patients Patients with Central Obesity Type I DM Patients Patients with inadequate medical history Patient having \<8% Patient who are not interested in the study are excluded.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
385 participants (estimated)

Study arms

  • Active comparator
    Control Group

    Routine healthcare practices and protocols for diabetes management. Regular advice on medication, diet, and lifestyle modifications in accordance with established guidelines, Follows conventional approaches. Lifestyle Modification(Provide guidance on how to maintain a healthy lifestyle, including balanced diet, exercise and regular sleep patterns). General Knowledge advancement. General knowledge about disease and medicine. Pill planner will be provided to keep them adherent to their medication. General Medication counselling.

    Other: Basic Education

  • Experimental
    Cognitive Behavioral Interventional Group

    Specific Patient-centered strategies beyond routine care designed to address individualized needs. Customized interventions, including pharmacist-led educational sessions, personalized counseling, or advanced lifestyle modifications. Aims to enhance patient outcomes by providing tailored and innovative solutions for better diabetes management. Change in lifestyle / link with any daily activity (Yoga and Meditation Specifically guide about food portions and how to balance each food group in daily routine along with recommended daily physical activity type and duration. Pill planner will also be provided to this group. Medication counselling, Insulin technique, Dose Adjustment, Titration, Insulin Correction. Cognitive Behavioral Therapy will be provided.

    Behavioral: Pharmacist-led Cognitive Behavioral therapy

Interventions

  • BehavioralPharmacist-led Cognitive Behavioral therapy

    Pharmacist-led Cognitive Behavioral therapy is patient centered approach that focus both physical and emotional aspect of health is provided. It is focused to identify negative and change negative thought pattern and behavior to improve mental and physical well being.Incorporation education about healthy meal choices, relaxation techniques, self management strategies,to improve education about potential adverse effect, how to recognize and on followup calls how to adjust medication doses along with this is provided.

  • OtherBasic Education

    Basic Education about lifestyle Modification(Provide guidance on how to maintain a healthy lifestyle, including balanced diet, exercise and regular sleep patterns). General Knowledge advancement. General knowledge about disease and medicine. Pill planner will be provided to keep them adherent to their medication. General Medication counselling.

06

What researchers measure

Primary outcomes

  1. Medication adherence score

    Adherence will be assessed using (Medication Adherence Reporting Scale) MARS-10. This scale describes three-dimension, Medication adherence behavior (1-4), attitude towards taking medication (5-8), negative side effects and attitudes to psychotropic medication (9-10). Each question has Yes and No response, a response consistent with adherence is coded as 1 and with non-adherence coded as 0. Higher the score higher will be the adherence. Adherence \<6 is poor adherence, and \>8 is high adherence.

    Time frame: 3 months

  2. Quality of life Score

    Patient's quality of life will be assessed using Revised Version of DQOL (RV-DQOL13 ; Audit of diabetes dependent quality of life) will be used to access the quality of life of the patient. Its scoring ranges from 1- 100

    Time frame: 3 months

Secondary outcomes

  1. Incidence of Drug-Drug Interactions

    Drug interactions among oral anti glycemic and other drugs will be assessed using standard website (update-Lexicomp) It is used to access the reduction in no. of drug drug interaction after pharmacist intervention in both control and Cognitive Behavioral Intervention groups.

    Time frame: 3 months

  2. HbA1c %

    HbA1c levels (%) will be assessed before the intervention is provided and after 3 months.

    Time frame: 3 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided — The sharing will be dependent on the consent provided by the patient.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2025; primary completion for Jul 2025, 5 months later.

Of 1,590 non-industry interventional studies with no phase under Diabetes Mellitus, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 5 months is below that.

Counting every sponsor, half of 1,750 studies reached it within 21 months; a quarter within 9 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 29, 2025
First posted
Feb 4, 2025
StartEst.
Feb 20, 2025
Primary completionEst.
Jul 30, 2025
CompletionEst.
Aug 31, 2025
Last update
Feb 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06807827
Lead sponsor
Hamdard University
Responsible party
Matti Ullah (Assistant Professor, Hamdard University) — Principal investigator
First posted
Feb 4, 2025
Start date
Feb 20, 2025 (estimated)
Primary completion
Jul 30, 2025 (estimated)
Completion
Aug 31, 2025 (estimated)
Last update
Feb 4, 2025

Study contacts

Matti Ullah, Ph.D Clinical Research
Contact
mattiullah@hamdard.edu.pk
+92-331-5056501
Iqra Farooq, M.Phil Pharmacy Practice
Contact

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion